# Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
Canonical URL: https://biopharmsignal.com/news/OLMA/olema-oncology-announces-preclinical-data-for-palazestrant-and-op-3136-at-the-2026-aacr-annual-meeting
Ticker: OLMA
Company: Olema Pharmaceuticals, Inc.
Source: Olema Pharmaceuticals, Inc.
Published: 2026-04-17 20:01 EST
Original Source URL: https://ir.olema.com
## Summary

Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle

## Article Body
Palazestrant’s mechanism of action confirmed; full recruitment of corepressor protein NCoR1 enables complete antagonism of the estrogen receptor OP-3136, in combination with palazestrant, exhibits synergistic anti-tumor activity in ER+/HER2- breast cancer models driven by suppression of cell-cycle
## Recent Company News
- 2026-05-26 11:00 EST — [Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-clinical-trial-collaboration-and-supply-agreement-with-bayer-to-evaluate-op-3136-in-combination-with-nubeqar-darolutamide-in-metastatic-castration-resistant-prostate-cancer) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-21 21:00 EST — [Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/OLMA/olema-oncology-announces-encouraging-initial-clinical-data-from-the-phase-1-study-of-op-3136-a-kat6-inhibitor-at-2026-asco-annual-meeting) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-12 11:00 EST — [Olema Oncology Reports First Quarter 2026 Financial and Operating Results](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-first-quarter-2026-financial-and-operating-results) — Source: Olema Pharmaceuticals, Inc.
- 2026-05-04 20:30 EST — [Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OLMA/olema-oncology-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Olema Pharmaceuticals, Inc.
- 2026-04-29 20:01 EST — [Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors](https://biopharmsignal.com/news/OLMA/olema-oncology-appoints-prakash-raman-ph-d-to-board-of-directors) — Source: Olema Pharmaceuticals, Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)